Compare TTI & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TTI | LTGO |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1996 | 2026 |
| Metric | TTI | LTGO |
|---|---|---|
| Price | $6.04 | $15.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $11.13 | ★ $52.25 |
| AVG Volume (30 Days) | ★ 2.5M | 251.3K |
| Earning Date | 11-02-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.30 | N/A |
| Revenue Next Year | $8.89 | N/A |
| P/E Ratio | $44.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.87 | $13.50 |
| 52 Week High | $12.54 | $25.93 |
| Indicator | TTI | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 56.90 | 46.79 |
| Support Level | $5.64 | $14.05 |
| Resistance Level | $6.31 | $17.12 |
| Average True Range (ATR) | 0.29 | 1.26 |
| MACD | 0.09 | 0.26 |
| Stochastic Oscillator | 88.09 | 58.30 |
Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments, namely Completion Fluids & Products and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. The Water & Flowback Services Segment provides onshore oil and gas operators with comprehensive water management services. The majority of revenue is from the Completion Fluids & Products segment.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.